10-K · June 10, 2026
Aethlon Medical, Inc. disclosed a diluted EPS loss of -10.61 for fiscal year 2026 against an estimate of -2.46, with no revenue generated. The operating expenses decreased by 21.9% year-over-year to approximately $7.3…
Earnings analysis · 10-Q
AEMD earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Aethlon reported a $4.02 diluted EPS loss, missing the $3.76 consensus estimate by $0.26, while revenue, margins, cash flow and segment results were not disclosed in the provided filing text. The company remains…
Read full summary
Aethlon reported a $4.02 diluted EPS loss, missing the $3.76 consensus estimate by $0.26, while revenue, margins, cash flow and segment results were not disclosed in the provided filing text. The company remains loss-making and financing-dependent, although management indicated that current resources should fund operations for at least 12 months following approximately $4.0 million raised after quarter-end. The filing reported no material risk-factor changes from the March 31, 2026 Annual Report.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-4.02
What stood out
-
EPS Missed Consensus
Aethlon reported a diluted EPS loss of $4.02, versus the $3.76 consensus estimate, a $0.26 miss or approximately 6.9%.
-
Controls Remained Effective
Management concluded that disclosure controls were effective as of June 30, 2026, and reported no changes in internal control over financial reporting during the quarter ended June 30, 2026 that materially affected, or were reasonably likely to materially affect, controls.
-
No Material Legal or Equity Actions
The company reported no material pending legal proceedings and no unregistered securities issuances during the three months ended June 30, 2026.
What to watch
-
Financing and Dilution Dependence
The company remains dependent on external financing. It raised approximately $4.0 million after quarter-end, while management said current resources fund operations for at least 12 months, indicating limited visibility beyond that period.
-
Ongoing Clinical-Stage Losses
The $4.02 diluted EPS loss and absence of disclosed revenue reflect continued clinical-stage execution risk and no demonstrated commercial revenue base in the reported period.
-
No Material Risk-Factor Improvement
The filing states there have been no material updates or changes to the risk factors in the Annual Report for the fiscal year ended March 31, 2026; therefore, no new risk mitigation or reduction was disclosed.
Management's outlook
No formal revenue or EPS guidance was provided. Management stated that current cash resources should fund operations for at least the next 12 months; quantitative outlook was otherwise deferred.
Earlier filings 4
10-Q · February 12, 2026
Aethlon Medical, Inc. reported a net loss of approximately $2,018,000 for Q3 2025, a noticeable increase from the prior year's net loss of $1,755,000. The earnings per share came in at a diluted loss of ($2.45),…
10-Q · November 12, 2025
Aethlon Medical, Inc. reported a substantial net loss of $1,487,100 for Q2 2025, a decline in EPS to -$3.74 compared to -$16.11 in Q2 2024, while total revenues remained at $0. The company's operating expenses…
10-Q · August 13, 2025
Aethlon Medical, Inc. reported no revenue for the second quarter of 2025, with a significant diluted EPS loss of -$3.70, reflecting continued financial strain. Operating expenses decreased by 31.6% year-over-year,…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.